9/12/2024

Valganciclovir Oral Presentations

Products Affected - Description

- Valganciclovir hydrochloride oral tablet, Cipla USA, 450 mg, bottle, 60 count, NDC 69097-0277-03 - discontinued

Reason for the Shortage

- Ajanta was not available to provide information.
- Camber has valganciclovir tablets available.
- Cipla discontinued valganciclovir tablets.
- Dr. Reddy's was not available to provide information.
- Granules has valganciclovir powder for solution available.
- H2 Pharma has Valcyte oral presentations available. Genentech transferred Valcyte to H2 Pharma (Cheplapharm's US partner) in April 2023.
- Major has valganciclovir tablets available.
- Somerset has valganciclovir powder for solution available.
- Teva did not provide a reason for the shortage.

Available Products

- Valcyte oral powder for solution, H2 Pharma, 50 mg/mL, 100 mL glass bottle, NDC 61269-0485-10
- Valcyte oral tablet, H2 Pharma, 450 mg, bottle, 60 count, NDC 61269-0480-60
- Valganciclovir hydrochloride oral powder for solution, Camber, 50 mg/mL, 100 mL glass bottle, NDC 31722-0837-10
- Valganciclovir hydrochloride oral tablet, Camber, 450 mg, bottle, 60 count, NDC 31722-0832-60
- Valganciclovir hydrochloride oral powder for solution, Granules, 50 mg/mL, 100 mL glass bottle, NDC 70010-0051-40
- Valganciclovir hydrochloride oral tablet, Major, 450 mg, unit-dose blister pack, 20 count, NDC 00904-6796-10
- Valganciclovir hydrochloride oral tablet, Major, 450 mg, unit-dose blister pack, 30 count, NDC 00904-6796-04
- Valganciclovir hydrochloride oral powder for solution, Somerset Therapeutics LLC, 50 mg/mL, 100 mL glass bottle, NDC 70069-0810-01
- Valganciclovir hydrochloride oral powder for solution, Teva, 50 mg/mL, 100 mL glass bottle, NDC 00591-2579-20

Estimated Resupply Dates

- Most marketed presentations are available.

Updated

Updated September 12, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 8, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.